Preprint has been published in a journal as an article
DOI of the published article
Preprint / Version 1

COVID-19: Implications for People with Chagas Disease


  • Ezequiel Zaidel Sanatorio Güemes, Buenos Aires, Argentina and Pharmacology Department, School of Medicine, University of Buenos Aires, Argentina
  • Colin Forsyth Drugs for Neglected Diseases initiative-Latin America, Rio de Janeiro, Brazil
  • Gabriel Novick Swiss Medical Group, Buenos Aires, Argentina and Friedman School of Nutrition Science and Policy, Tufts University, Boston, USA
  • Rachel Marcus Latin American Society of Chagas, Washington, DC, USA
  • Antonio Luiz Ribeiro Internal Medicine Department, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil and Hospital das Clínicas, UFMG, Belo Horizonte, Brazil
  • Maria Jesus Pinazo ISGlobal Hospital Clínic - University of Barcelona, Barcelona, Spain
  • Carlos Morillo Libin Cardiovascular Institute, University of Calgary, Calgary, Canada
  • Luis Eduardo Echeverria Department of Cardiology, Cardiovascular Foundation of Colombia, Floriblanca, Colombia
  • Maria Aparecida Shikanai-Yasuda Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, São Paulo, Brazil
  • Pierre Buekens Tulane University School of Public Health and Tropical Medicine, New Orleans, USA
  • Pablo Perel World Heart Federation, Geneva, Switzerland and Department of Non Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
  • Sheba Meymandi Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, Sylmar, USA
  • Kate Ralston World Heart Federation, Geneva Switzerland
  • Fausto Pinto World Heart Federation, Geneva, Switzerland and Department of Cardiology, CCUL, Lisbon School of Medicine, Universidade de Lisboa, Portugal
  • Sergio Sosa-Estani Drugs for Neglected Diseases initiative-Latin America, Rio de Janeiro, Brazil and Epidemiology and Public Health Research Center, (CIESP-CONICET), Buenos Aires, Argentina



Chagas disease, COVID-19, neglected tropical diseases (NTDs)


As the global COVID-19 pandemic advances, it increasingly impacts the vulnerable populations who already bear a heavy burden of neglected tropical diseases. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastrointestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19’s potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.


Download data is not yet available.


Metrics Loading ...



How to Cite

Zaidel, E., Forsyth, C., Novick, G., Marcus, R., Ribeiro, A. L., Pinazo, M. J., Morillo, C., Echeverria, L. E., Shikanai-Yasuda, M. A., Buekens, P., Perel, P., Meymandi, S., Ralston, K., Pinto, F., & Sosa-Estani, S. (2020). COVID-19: Implications for People with Chagas Disease. In SciELO Preprints.


Health Sciences